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Abstract
Background: Despite a decreasing incidence of peptic ulcer disease, most previous studies report
a stabile incidence of ulcer complications. We wanted to investigate the incidence of peptic ulcer
complications in Sweden before and after the introduction of the proton pump inhibitors (PPI) in
1988 and compare these data to the sales of non-steroid anti-inflammatory drugs (NSAID) and
acetylsalicylic acid (ASA).
Methods: All cases of gastric and duodenal ulcer complications diagnosed in Sweden from 1974
to 2002 were identified using the National hospital discharge register. Information on sales of ASA/
NSAID was obtained from the National prescription survey.
Results: When comparing the time-periods before and after 1988 we found a significantly lower
incidence of peptic ulcer complications during the later period for both sexes (p < 0.001). Incidence
rates varied from 1.5 to 7.8/100000 inhabitants/year regarding perforated peptic ulcers and from
5.2 to 40.2 regarding peptic ulcer bleeding. The number of sold daily dosages of prescribed NSAID/
ASA tripled from 1975 to 2002. The number of prescribed sales to women was higher than to
males. Sales of low-dose ASA also increased. The total volume of NSAID and ASA, i.e. over the
counter sale and sold on prescription, increased by 28% during the same period.
Conclusion: When comparing the periods before and after the introduction of the proton pump
inhibitors we found a significant decrease in the incidence of peptic ulcer complications in the
Swedish population after 1988 when PPI were introduced on the market. The cause of this
decrease is most likely multifactorial, including smoking habits, NSAID consumption, prevalence of
Helicobacter pylori and the introduction of PPI. Sales of prescribed NSAID/ASA increased,
especially in middle-aged and elderly women. This fact seems to have had little effect on the
incidence of peptic ulcer complications.
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Background
Peptic ulcer complications have a high mortality, espe-
cially in elderly patients [1] and it is therefore important
to understand the epidemiology of this disease in order to
investigate if complications can be prevented. Despite
new efficient drugs to treat peptic ulcer disease and
increasing knowledge about its aetiology, the incidence of
peptic ulcer complications, i.e. perforation and bleeding,
have been reported by several groups to be unchanged
(table 1). However, in a previous study from Lund Univer-
Table 1: Reported incidences of peptic ulcer complications (cases per 100000 inhabitants per year).
Country (ref) Period Reported 
incidences
Comment Studied variable
perforation Bleeding
Norway (18) 1935–1990 About 10 Report birth cohort specific risks for 
perforation
Admittance rates
USA (44) 1956–1985 10-5 7-4 Relatively stable incidence of emergency 
operations for PUC
Emergency operations
England and
Wales (13)
1958–1962
1979–1982
Increasing incidence of PUC* and 
NSAID use in elderly 
National register
Scotland (13) 1958–1962
1979–1982
Increasing incidence of PUC* and 
NSAID use in elderly 
National register
USA (45) 1974–1976
1984-1984
No rate per 100000 
inhab
No rate per 100000 
inhab
13% increase in perforations and 7% 
increase in bleedings after H2-rec 
blocker introduction
Cases operated
Poland (11) 1977–1996 No rate per 100000 
inhab
Constant number/year, increasing % 
elderly women, increasing mean age
Cases operated
Hong-Kong (19) 1979–1985 14–18 Operating room
logbooks
New South 
Wales (19)
1979–1985 3–4 Diagnosis reported to 
dept of heath
Finland (12,46) 1972–1987
1987–1999
4–5
5–7
3–4 Increasingly more , increasing mean 
age
Cases operated, 
national register
Sweden (1) 1974–92 2–11 Significant decrease in incidence Patients records
Denmark (20) 1974–1984 4–10 5–10 No significant difference before/after 
H2-receptor blockers
Cases operated
Finland (17) 1977–1989 2–8 3–9 No significant difference before/after 
H2-receptor blockers
Cases operated
Finland (15) 1979-85-00 3-6-4 No significant difference before/after 
H2-receptor blockers or PPI
Patients records
UK (10) 1989–99  10–11
 7-7
27–31
14–16
Admittance rates
UK (47) 1996–98  5
 4
Only duodenal perforations, increasing 
mean age in 
Patients records
Germany (23) 1989–90
1999-00
51
49
Patients older and more NSAID use in 
the later period
Prospective
*PUC = peptic ulcer complicationsBMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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sity Hospital we found a fall in the incidence of peptic
ulcer perforation from 1974 to 1992 in our primary
uptake area [1]. We wanted to investigate the incidence of
peptic ulcer complications in a larger population before
and after the introduction of the Proton pump inhibitors
(PPI) in order to investigate whether the introduction of
this ulcer healing drug has influenced the incidence of
these diseases.
Well-designed studies have clearly shown that NSAID and
ASA contribute to the development of peptic ulcer disease
and upper gastro-intestinal complications in a dose-
dependent manner [2-10]
In a study from the United Kingdom, Walt et al reported
increasing sales of NSAID during the 1970's and 1980's to
elderly women, a cohort that has also been reported to
have an increasing incidence of peptic ulcer complications
[1,11-14]. Increased use of ASA and NSAID might influ-
ence the incidence of peptic ulcer complications over
time. A recent Danish study report increased overall use of
NSAID after the introduction of the selective COX-2
inhibitors in 1999 [15]. This phenomenon coincided with
a stable hospitalization rate of peptic ulcer bleeding but a
decrease in hospitalization for perforated peptic ulcer in
their study. We wanted to study if a correlation between
sales of NSAID and complications to peptic ulcer compli-
cations could be found in the Swedish population and
thus we further studied the sales of prescribed ASA and
NSAID in Sweden during the same period.
Methods
The population of Sweden increased from 8,2 millions in
1974 to 8,9 millions in 2002. The Swedish national
health system is tax funded giving the whole population
unrestricted access to health services.
Data on incidence of ulcer complications
In this study all cases of gastric and duodenal ulcer com-
plications diagnosed in Sweden from 1974 to 2002 were
identified using the National Hospital Discharge Register
(National Board of Health and Welfare, S-10630, Stock-
holm, Sweden). Since 1987 it is mandatory for hospitals
to report to this register. In practise, however, it has been
in existence since the early seventies though not in the
entire country. We compensated for this when the inci-
dence figures from 1974 to 1986 were calculated, as
described below.
The ICD codes used for the search are listed in table 2. In
ICD 8 and ICD 9 there are codes named ".99" or ".9" in
the last positions which represent "unspecified location
without knowledge of bleeding or perforation". These
codes does not exist in ICD 10 which means that the
patients that were earlier coded as totally unspecified are
now included in other codes. This fact could mean that
incidences of ulcer complications are underestimated
before 1997 when ICD 10 was introduced. During the
period 1974–86 between 30–37% of all reported codes
for peptic ulcer disease were reported as "totally unspeci-
fied". From 1987 to1996 this number was 16–20%
Table 2: Codes searched for in the national register
Ulcer complication ICD 8
(-1986)
ICD 9
(1987–96)
ICD 10
(1997-)
Perforated gastric ulcer 53100, 53101 5311, 5312
5315, 5316
K251, K252
K255, K256
Perforated duodenal ulcer 53200 5321, 5322
5325, 5326
K261, K262
K265, K266
Other perforated ulcer 53300, 53400 5331, 5332
5335, 5336
5341, 5342
5345, 5346
K271, K272
K275, K276
K281, K282
K285, K286
Bleeding gastric ulcer 53190, 53193 5310, 5312
5314, 5316
K250, K252
K254, K256
Bleeding duodenal ulcer 53290 5320, 5322
5324, 5326
K260, K262
K264, K266
Other bleeding ulcer 53390, 53490 5330, 5332
5334, 5336
5340, 5342
5344, 5346
K270, K272
K274, K276
K280, K282
K284, K286BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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according to the National Department of Health. Codes
representing ulcer with bleeding as well as perforation are
included in both the bleeding and the perforation groups.
The data from the National Department of Health are reli-
able. In a study from 1994 regarding validity, they found
that in 11–14% of the cases the diagnosis reported was
not correct if they applied a very strict judgement, i.e. all
five figures correct [16]. If they were slightly less stringent,
i.e. three figures correct, the inaccurate diagnoses was
about 6–8%.
Data on sales of NSAID/ASA
Information on sales of NSAID was obtained from the
National Prescription Survey (The National Corporation
of Swedish Pharmacies – Apoteket AB). Data on drugs dis-
pensed on prescription during the period 1975 – 1986
used a sample of 1/288 of all dispensed prescriptions.
From 1987 – 2002, the sample was 1/25 (4%) of all dis-
pensed prescriptions. However, medication to patients in
Nursing Homes, Hospices etc. is only included if their
medication had been dispensed on prescription by the
pharmacies.
The composition of the combination-product Treo
Comp® was changed in 1985, and the ATC-code was
changed accordingly from N02BA71 (ASA, combinations
with psycholeptics) to N02AA59 (codeine combinations).
The DDD for Treo Comp® is 3 tablets, corresponding to
1,5 g ASA, but the DDD for ASA is 3 g. One DDD of Treo
Comp® thus corresponds to 0,5 DDD ASA. The figures for
Treo Comp® have been recalculated to DDD's of ASA.
Statistics
Age-standardised incidence rates were calculated using the
Swedish population in 1995 as an external reference. Yearly
site, age and gender specific incidence rates were calculated
using data from the national population register. Time
trends were investigated using linear regression analysis
with log(incidence) rates as the dependent variable and the
Incidence of gastric perforated peptic ulcers in Sweden from 1974 to 2002 Figure 1
Incidence of gastric perforated peptic ulcers in Sweden from 1974 to 2002. Note that the y-axis has been truncated.BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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Incidence of duodenal perforated peptic ulcers in Sweden from 1974 to 2002 Figure 2
Incidence of duodenal perforated peptic ulcers in Sweden from 1974 to 2002. Note that the y-axis has been trun-
cated.
Table 3: Spline regression analysis, Gastric perforated ulcers
Males Females
Year Coef. 95% Conf. interval Coef. 95% Conf. interval
1975 -0.14 -0.41
0.13
0.03 -0.19
0.25
1980 0.01 -0.04
0.05
0.06 0.03
0.10
1985 0.01 -0.03
0.05
0.04 0.01
0.08
1990 0.04 -0.001
0.08
0.03 -0.003
0.06
1995 -0.07 -0.1
-0.03
-0.02 -0.05
0.01
2000 -0.08 -0.11
-0.05
-0.10 -0.12
-0.07BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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calendar year as an independent variable. An exploratory
spline regression analysis of log incidence with 6 uniformly
distributed knots was also performed using a piecewise lin-
ear function for time. STATA 10.1 was used for the statisti-
cal calculations. All p-values are two-sided and p-values
below 5% were considered statistically significant.
The ethical committee of Lund University Hospital
approved the study.
Results
Age Standardised incidence
Perforated Peptic Ulcer in Males
The incidence of gastric perforation varied from 3.5 to 7.8
and for duodenal perforation from 2.3 to 6.4 per100 000
inhabitants per year. There were slightly more gastric per-
forations throughout the whole period. From 1974 to
1988 there was a rise in incidence (p < 0.002) and from
1988 to 2002, a fall in incidence (p < 0.001) according to
the linear regression analysis. The spline regression analy-
ses regarding perforations in males are presented in tables
3 and 4 as well as in figures 1 and 2. The results are similar
to the linear regression analysis.
Bleeding Peptic Ulcer in Males
The incidence of bleeding gastric ulcer varied from 14.9 to
40.2 and for bleeding duodenal ulcer between 15.0 to
40.0 per100 000 inhabitants per year. From 1974 to 1988
there was a rise in incidence (p < 0.001) and from 1988
and 2002 a fall in incidence (p < 0.001) according to the
linear regression analysis. The spline regression analyses
regarding bleeding in males are presented in tables 5 and
6 as well as in figures 3 and 4. The results are similar to the
linear regression analysis
Perforated Peptic Ulcer in Females
The incidence of gastric perforation varied between 2.7 to
5.8 and for duodenal perforation from 1.5 to 4.0 per 100
000 inhabitants per year. There were relatively more gastric
than duodenal perforations during the whole period.
Between 1974 and 1988 there was an increase in incidence
(p < 0.001) and from 1988–2002 a fall in incidence (p <
0.001) according to the linear regression analysis. The
spline regression analyses regarding perforations in females
are presented in tables 3 and 4 as well as in figures 1 and 2.
The results are similar to the linear regression analysis
Bleeding Peptic Ulcers in Females
The incidence of bleeding gastric ulcers varied between
9.6 and 24.2 and for bleeding duodenal ulcers from 5.2
to13.6 per100 000 inhabitants per year in females. There
were relatively more gastric than duodenal bleeding ulcers
during the whole period. Between 1974 and 1988 there
was an increase in incidence (p < 0.001) and from 1988
to 2002 a decrease in incidence (p < 0.001) according to
the linear regression analysis. The spline regression analy-
ses regarding bleeding in males are presented in tables 5
and 6 as well as in figures 3 and 4. The results are similar
to the linear regression analysis
Sales of NSAID and ASA
The sales of prescribed NSAID and ASA in Sweden for the
years 1975 through 2002 are presented in figures 5, 6, 7,
8 and 9. In males the sales of NSAID and ASA described as
DDD per1000 inhabitants per day rose from 2.3 to13.1 in
the age group 0–50 years, from 13.7 to 52.1 in the age
Table 4: Spline regression analysis, Duodenal perforated ulcers
Males Females
Year Coef. 95% Conf. interval Coef. 95% Conf. interval
1975 -0.17 -0.44
0.09
-0.21 -0.58
0.16
1980 0.01 -0.04
0.05
-0.00 -0.06
0.06
1985 0.02 -0.02
0.06
0.10 0.04
0.16
1990 0.03 -0.004
0.07
0.05 -0.01
0.10
1995 -0.05 -0.09
-0.01
-0.04 -0.09
0.01
2000 -0.11 -0.14
-0.08
-0.09 0.13
0.05BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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group 51–70 years and from 20.3–59.1 in the age group
71–99 years.
The corresponding figures for females were from 3.2 to
20.9 in the age group 0–50 years, from 21.0 to 82.5 in the
age group 51–70 years and from 30.6 to 80.8 in the age
group 71–99 years.
The sales to females compared to males were higher in all
age groups and the difference increased towards the end of
the study period.
The total sales of prescribed NSAID/ASA (DDD per1000
inhabitants per day) increased from 13.3 in 1978 to 46.5
in 2002.
The total volume of NSAID and ASA (DDD per1000
inhabitants per day) sold both "over the counter" and pre-
scription sales, increased from 45.0 in 1978 to 57.6 in
2002 according to the statistics of Apoteksbolaget AB,
Sweden. This means that sales increased 28% during this
period.
The sales of low-dose ASA (DDD per1000 inhabitants per
day) in males increased from 2.75 to 3.55 in the age group
0–50 years, from 79.2 to 110.9 in the age group 51–70
years and from 219.0–356.2 in the age group 71–99 years
(fig 7).
The sales of low-dose ASA (DDD per1000 inhabitants per
day) in females increased from 1.5 to 2.0 in the age group
0–50 years, from 42.3 to 64.2 in the age group 51–70
years and from 156.4–288.9 in the age group 71–99 years
(fig 8).
Sales of acid inhibitors
H2 receptor blockers were introduced in Sweden in 1978.
In 2002 total sales were 5.7 DDD per1000 inhabitants per
day (figure 9).
Incidence of gastric bleeding peptic ulcers in Sweden from 1974 to 2002 Figure 3
Incidence of gastric bleeding peptic ulcers in Sweden from 1974 to 2002. Note that the y-axis has been truncated.BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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The first PPI were introduced in Sweden in 1988. In 2002
total sales were 30.5 DDD per1000 inhabitants per day
(figure 9).
Mean age
In the whole material mean age rose from 59.0 years to
67.9 years from 1974 to 2002. The mean age in males
with gastric complications rose from 59 years in 1974 to
66.5 years in 2002 The corresponding figures for females
were 63.2 and 70.2 years.
The mean age in males with duodenal complications rose
from 52.8 years in 1974 to 62.1 years in 2002. In females
the corresponding figures were 61.1 and 72.6.
Discussion
In the mid-eighties two events took place that changed the
treatment of peptic ulcer patients. First the discovery of
the connection between Helicobacter pylori and peptic
ulcer disease and second the introduction of the first PPI
in 1988. However, despite new and efficient treatment
regimes several authors report that the incidence of com-
plications of peptic ulcer disease, perforation and bleed-
ing, has been relatively unchanged during the last thirty
years of the 20-th century [1,11-14,17-26]. In contrast we
found a significant fall in incidence of both bleeding and
perforated ulcers in the Swedish population after 1988
despite increasing sales of ASA and NSAID, drugs known
to be ulcerogenic.
Incidence of peptic ulcer complications
According to the literature, the incidence of peptic ulcer
complications appears to be relatively stable over the last
three decades with approximately 5 to10 episodes per 100
000 inhabitants/year. Some relevant references are listed
in table 1. In elderly women, several authors even report
an increasing incidence [11-14,27]. At least three studies
have compared the incidences of peptic ulcer perforation
Incidence of duodenal bleeding peptic ulcers in Sweden from 1974 to 2002 Figure 4
Incidence of duodenal bleeding peptic ulcers in Sweden from 1974 to 2002. Note that the y-axis has been truncated.BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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before and after the introduction of the H2-receptor
antagonists but found the incidence to be unchanged
[1,22,23]. In contrast to these studies, we report a signifi-
cant decrease in peptic ulcer complications in the Swedish
population over the last two decades. Recently, a Danish
group report similar results from 1996 to 2004 regarding
perforated peptic ulcer but not for bleeding ulcers [15].
Like us they had a relatively large sample size, the Danish
study involved a population of 1, 2 million inhabitants. A
plausible explanation for the fact that several studies fail
to detect any differences might be that the studied popu-
lations have often been too small for a disease that has a
relatively low incidence to begin with. Differences in the
prevalence of the different risk factors for peptic ulcer
complications between populations, which will be dis-
cussed below, are other possible explanations.
The significant drop in incidence of peptic ulcer complica-
tions reported in this study, can possibly be explained by
a generational (cohort) influence, for example less expo-
sure to Helicobacter pylori infections among younger gen-
erations compared with older birth cohorts. Another
possibility is a secular (periodical) phenomenon, for
example the influence of extensive exposure of acid-sup-
pressing drugs or changing trends in the use of factors
known to cause ulcer or counteract ulcer healing, such as
Table 6: Spline regression analysis, Duodenal bleeding ulcers
Males Females
Year Coef. 95% Conf. interval Coef. 95% Conf. interval
1975 -0.23 -0.52
0.06
-0.23 -0.53
0.08
1980 0.01 -0.03
0.06
0.05 -0.004
0.10
1985 0.04 -0.004
0.08
0.06 0.02
0.11
1990 0.05 0.003
0.09
0.06 0.01
0.11
1995 -0.10 -0.14
-0.05
-0.07 -0.11
-0.02
2000 -0.09 -0.12
-0.05
-0.09 -0.13
-0.06
Table 5: Spline regression analysis, Gastric bleeding ulcers
Males Females
Year Coef. 95% Conf. interval Coef. 95% Conf. interval
1975 -0.13 -0.38
0.12
-0.14 -0.42
0.15
1980 0.03 -0.14
0.07
0.04 -0.005
0.09
1985 0.01 -0.02
0.53
0.04 -0.005
0.08
1990 0.07 0.03
0.11
0.08 0.03
0.12
1995 -0.07 -0.10
-0.03
-0.07 -0.11
-0.03
2000 -0.12 -0.14
-0.09
-0.11 -0.14
-0.08BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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tobacco, alcohol or ulcerogenic drugs. Further, the use of
gastroscopy has probably increased during the study
period in Sweden enabling the detection and treatment of
symptomatic peptic ulcers before complications occur. In
our opinion, the explanation for this uniform decline in
complications after 1988 is most likely multifactorial.
In the sections below we will discuss some important risk
factors for complicated peptic ulcer disease and their pos-
sible influence on our results. When interpreting the
results one must be aware that this is an ecological study
with risk of "ecological fallacy" [28]. The connections dis-
cussed below can, of course, be caused by other factors
and should therefore be adopted with caution.
NSAID as a risk factor and influence of PPI
We found an increase in the sales of prescribed NSAID
during the study period. The number of prescriptions
increased with age and was highest among middle-aged
and elderly women. As mentioned earlier, elderly women
are also the group in which the incidences of peptic ulcer
complications are reported to be increasing relative to
other groups [1,11-14]. However, in conjunction with an
increase of prescribed sales there was a fall in non-pre-
scribed sales, resulting in a total increase in NSAID sales
of 28% during this period.
Several studies support the notion that NSAID is a risk fac-
tor not only in uncomplicated peptic ulcer disease, but
also in regard to perforated and bleeding ulcers [2,3,5-
7,10,29,30]. A systematic review of 18 case-control studies
from 1990 to 1999 reported a pooled RR of 3.6 [2]. The
higher risk was maintained during treatment and disap-
peared after treatment termination. The added risk is
dose-dependent and also includes low-dose ASA. Studies
report higher risk with all doses, with a RR = 2 for bleeding
ulcer with daily intake of 75 mg ASA [8,9]. According to a
study by Sorensen et al from 2000 the risk increase further
when low-dose ASA is combined with NSAID [10].
Bearing this in mind one would expect a rise in incidence
of peptic ulcer complications when the sales of NSAID
increases, which is quit contrary to our findings. Since
ours is a descriptive study one can only speculate as to the
relationship between peptic ulcer complications and
NSAID use. In a recent German paper from 2005 Ohm-
ann et. al. found no difference in the incidence of peptic
ulcer bleeding when comparing the years 1989 and 1999
despite significantly higher NSAID consumption in the
latter year [26]. Hawkey conducted a prospective, control-
led study of patients with bleeding ulcers and found that
H pylori-positive NSAID users had twice the risk compared
to H pylori negative patients [31]. The prevalence of H
pylori is declining and thus could have reduced the effect
of increased NSAID use [32-34].
In the end of the 1990-ies the less ulcerogenic selective
cyclo-oxygenase-2 (COX-2) inhibitors were introduced in
Sweden. These drugs were not included in this study since
they were only available for use in Sweden during the last
years of the study period. Christensen et al report a 44%
rise in prescriptions of all NSAID after 1997, mainly due
to COX-2 inhibitors [15]. The hospitalization rates of pep-
tic ulcer complications after the introduction of COX-2
inhibitors were, however, stable for bleeding ulcers and
decreased from 17 to 12/100000 person-years from 1996
to 2004 for perforations. This indicates that the COX-2
selective drugs might have decreased the risk of peptic
ulcer complications for the individual NSAID user.
Proton pump inhibitors (PPI) have become one of the
most sold drugs in the world and are nowadays also avail-
able over the counter in Sweden. It is a well known fact
that PPI protect against peptic ulcer complications in
NSAID users [3,35-38]. Interestingly the introduction of
Sales of prescribed NSAID and ASA between 1975–2002 in  Sweden among females Figure 6
Sales of prescribed NSAID and ASA between 1975–
2002 in Sweden among females.
Sales of prescribed NSAID and ASA between 1975–2002 in  Sweden among males Figure 5
Sales of prescribed NSAID and ASA between 1975–
2002 in Sweden among males.
BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
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PPI was almost simultaneous with the beginning of a fall-
ing incidence in peptic ulcer complications (fig 1, 2, 3, 4).
We believe that the extensive use of PPI in the population
of Sweden has reduced the incidence of peptic ulcer com-
plications. This conclusion is supported by Vonkeman et
al (2007) who performed a nested case-control study
from a cohort of 52000 NSAID users [39]. They found a
significant risk reduction regarding peptic ulcer complica-
tions in NSAID users who used PPI concomitantly. Selec-
tive COX-2 inhibitors did not reduce the risk in their
study.
Is Helicobacter pylori a risk factor in complicated peptic 
ulcer disease?
In the present study we found a significant decrease in
peptic ulcer complications in the mid-eighties that co-
inside with the discovery of H pylori as a cause for peptic
ulcer disease. H pylori is an important pathogenic factor in
uncomplicated peptic ulcer disease, although studies that
investigate the connection between H pylori and peptic
ulcer complications are somewhat divergent. For example,
Gisbert et. al. (2003) calculated a mean prevalence of 68%
from 19 studies with a range from 0–100% [40].
We have found five studies comparing patients with pep-
tic ulcer complication patients to patients with non-GI
related diseases in the control group. In three of these
reports there was no difference in the prevalence of H
pylori  [5,41-44]. Three studies have compared patients
with peptic ulcer complications patients to patients with
uncomplicated ulcer disease [43,45,46]. Surprisingly, the
prevalence of H pylori was slightly higher in the latter
group.
Helicobacter Pylori is, without a doubt, connected to peptic
ulcer disease. In the pathogenesis of perforation and
bleeding, however, other factors such as NSAID and
smoking are of great importance as well. In the time
period covered by this study, the prevalence of H pylori
infections has decreased in the western world [47] as has
the incidence of peptic ulcer complications in our study
(fig 1, 2, 3, 4). Since this is a descriptive study one can
only speculate as to whether these two phenomena are
correlated or not. There is however no doubt in the litera-
ture that eradication of H pylori is mandatory after a peptic
ulcer complication, if the patient is H pylori positive. Oth-
erwise the risk of recurrent ulcer disease is high [48-50].
What about smoking?
Smoking is a risk factor for peptic ulcer perforation
[5,18,51]. A prospective cohort study from Denmark
found that smoking > 15 cigarettes daily increased the risk
of peptic ulcer perforation 3,5 times [51]. A retrospective
study from Norway report that a cohort pattern in preva-
lence of smoking partly explained the cohort pattern in
perforation risk for both sexes [18]. The prevalence of
smoking has declined during the last twenty years in Swe-
den, especially in men, which could perhaps account for
fewer ulcer complications [52].
Sales of gastric acid inhibitors and NSAID:s in Sweden 1978– 2002 Figure 9
Sales of gastric acid inhibitors and NSAID:s in Swe-
den 1978–2002.
Sales of prescribed low-dose ASA between 1997–2002 in  Sweden among females Figure 8
Sales of prescribed low-dose ASA between 1997–
2002 in Sweden among females.

Sales of prescribed low-dose ASA between 1997–2002 in  Sweden among males Figure 7
Sales of prescribed low-dose ASA between 1997–
2002 in Sweden among males.
BMC Gastroenterology 2009, 9:25 http://www.biomedcentral.com/1471-230X/9/25
Page 12 of 13
(page number not for citation purposes)
Conclusion
When comparing the periods before and after the intro-
duction of the proton pump inhibitors we found a signif-
icant decrease in the incidence of peptic ulcer
complications in the Swedish population after 1988 when
PPI were introduced on the market. The cause of the
decrease is most likely multifactorial, including smoking
habits, NSAID consumption, prevalence of Helicobacter
pylori and the introduction of the PPI.
Patients with peptic ulcer complications are in average ten
years older in 2002 than twenty years earlier. Sales of pre-
scribed NSAID/ASA increased, especially in middle-aged
and elderly women. This fact seems to have had little
effect on the incidence of peptic ulcer complications, pos-
sibly because of a protective role of the PPI.
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